DEA's 7-OH Schedule I Action Will Drive a Wave of Opioid Patients to Treatment Centers

Why it matters

The DEA's move to place concentrated 7-OH in Schedule I will not erase existing dependence — it will redirect it to emergency rooms and addiction treatment centers, many of which have never encountered this patient population. Clinicians who understand the compound now will be better positioned when patients arrive.

The big picture

7-hydroxymitragynine (7-OH), sold legally for years as a gas-station supplement, was chemically engineered to concentrate an opioid-active alkaloid far beyond any level found in the natural kratom plant. The DEA's July 1, 2026, intent to temporarily place it in Schedule I targets enhanced and synthetic products, not botanical kratom leaf. But the scheduling does not dissolve the biology of dependence in people already using these products daily.

Key findings

• DEA announced July 1, 2026, intent to temporarily schedule concentrated 7-OH and three synthetic relatives into Schedule I, effective no earlier than August 5, 2026
• Hospitalizations linked to kratom products rose from 43 in 2015 to 538 in 2025 at one Virginia poison center alone — a more than tenfold increase
• 7-OH was marketed as a plant-based supplement while binding the same brain receptor as morphine and heroin, leaving many users unaware they were using an opioid
• Dependence cases will not resolve at banning — affected individuals face withdrawal, treatment-seeking, or potential migration to illicit opioid supply
• 7-OH dependence responds to existing evidence-based tools including buprenorphine and methadone, but treatment providers must first recognize the clinical presentation

What they say

The addiction field has seen this sequence before — closing one supply without addressing the underlying dependence tends to divert demand rather than end it. What is different this time is that the substance was sitting by the register, and the people it caught mostly thought they were buying something safe.

Bottom line

The DEA's 7-OH scheduling will send an underserved, unrecognized patient population into the addiction treatment system — providers need to prepare now.